Competition for kidney transport may retain toxic waste during synchronized tissue renewal
Coincident tissue renewal may let less toxic metabolites monopolize organic anion transporter 1, delaying toxic waste removal. Separating the flows should end retention; absent retention plus protection from blocking mineral particles would favor a rival explanation.
Stage of verification
- Hypothesis published2026-10-06
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Lens
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Rhythm or programme
Tissue renewal cycles
Cycles through which tissues renew themselves and release breakdown products
Where this hypothesis actsAcross tissues whose breakdown products compete for renal OAT1 transport
Hypotheses on this target 1
Inhibition
Activation
Function preservation
Feedback restoration
Rhythm restoration1
Direct measurement
What is proposed
Rhythm restoration
Stagger tissue renewal cycles to separate competing metabolite flows in time
With whatNot stated in the record
HowUse a tissue renewal mimetic that distributes renewal over time, reducing overlap between flows of competing OAT1 substrates
Possible result
Possible reduction in toxic anion retention and chronic kidney and vascular damage
From the recordРазнесённое обновление уменьшает конкурентное вытеснение и межцикловую задержку токсичных анионов.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
The timing of tissue renewal could matter as much as the amount of waste it produces. The unexpected proposal is that a less toxic waste product could make another product more dangerous by occupying the kidney transport protein both need, even when total daily removal remains sufficient. This is a hypothesis generated by the pipeline, not a measured result.
- Simultaneous tissue renewal is proposed to release different waste products into overlapping streams.
- Those products are proposed to compete for the same OAT1 transport sites in kidney cells.
- A more strongly binding product is predicted to occupy transport sites and delay a more toxic, weaker-binding product.
- The toxic product is predicted to remain between renewal cycles, despite sufficient total removal over a day.
- Separating the waste streams in time is predicted to reduce competition and the resulting delay.
- Reduced persistence of toxic waste is proposed to lessen lasting kidney and blood-vessel damage.
Two kinds of rubbish need the same collection vehicle. If harmless rubbish repeatedly takes the available space, dangerous rubbish can wait longer even though the vehicle carries enough total rubbish over the day.
Where the picture breaks: Molecules do not claim places in a queue. Their transport depends on free concentrations, binding and movement through the protein, and entry into a kidney cell is not the same as removal from the body.
- Master questionstep 01 of 04
Imitating beneficial processes already performed by the body might provide new ways to extend life through substances, combinations or other interventions.
Rests on: The goal is to generate mechanisms through which reproducing a physiological process could extend life.
AssumptionThe goal takes as a working possibility that useful effects of bodily processes can be reproduced by interventions and translated into longer life; the supplied material does not establish that outcome.
- Goal pillarstep 02 of 04
Repeated interventions are considered in terms of whether each cycle of the response they imitate reaches completion.
Rests on: The master question seeks beneficial effects from imitating bodily processes, but does not identify completion of repeated responses as a requirement.
AssumptionCompletion of each repeated response is selected as a relevant condition for benefit. The supplied stage does not define completion or explain its connection to lifespan.
- Gap questionstep 03 of 04
Making several tissues renew together might shorten life if their combined waste peaks exceed the kidneys’ removal capacity, while keeping their cycles offset might preserve the benefit.
Rests on: The preceding stage names completion of repeated responses, but provides no account of tissue timing, waste peaks or kidney removal.
LeapThe missing connection is evidence or an explicit rationale showing that the imitated responses produce coincident waste loads large enough to exceed kidney removal capacity and affect lifespan. The screened sources do not establish this connection.
- Hypothesisstep 04 of 04
Different products of tissue renewal are proposed to compete for OAT1. A product with higher affinity, meaning stronger binding to the transport protein, could delay a more toxic product with weaker binding, making the composition and timing of waste matter even when daily removal remains adequate.S8
Rests on: The preceding question supplies the concern about coincident waste streams. S8, in Asian journal of pharmaceutical sciences (2020), reports competitive transport interactions between imipenem and cilastatin through OAT1 and the related organic anion transporter 3 (OAT3) in cell models and rats; it does not establish competition between tissue-renewal products or protection from separating their arrival. The hypothesis also borrows a proportional sharing rule from economics to model how substances divide limited transport sites, with concentrations, binding strengths and transport rates measured independently.
Supported by literature
What is carried, and what is not. The screened literature speaks to one central link in the six-link mechanism: competition for kidney transport. S8, in Asian journal of pharmaceutical sciences (2020), reports competition between two drugs in cell models and rats, but neither it nor the other supplied sources establishes the sequence from synchronized tissue renewal to persistent toxic waste, lasting injury or shorter life.S8
Where the reasoning is carried by something unstated · 3
- Master question. The goal takes as a working possibility that useful effects of bodily processes can be reproduced by interventions and translated into longer life; the supplied material does not establish that outcome.
- Goal pillar. Completion of each repeated response is selected as a relevant condition for benefit. The supplied stage does not define completion or explain its connection to lifespan.
- Gap question. The missing connection is evidence or an explicit rationale showing that the imitated responses produce coincident waste loads large enough to exceed kidney removal capacity and affect lifespan. The screened sources do not establish this connection. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Equal numbers of incoming molecules could be mistaken for equal competition at OAT1. Replacing one substance can change the free concentration, meaning the amount unbound and available to interact with the transporter, so a longer delay alone would not establish the proposed dependence on binding strength. What closes it: The proposed test requires independently measured free concentrations and binding strengths for substances experimentally established to use the same transporter. Its quantitative prediction must use those measurements rather than total input alone.
- Greater entry into kidney cells could be mistaken for better removal from the body, although the substance might accumulate inside those cells. What closes it: As the supplied testing outline requires, uptake from the blood-facing side of kidney cells and exit into urine must be measured separately. Measurements of the substance inside cells and in the circulating fluid are needed to distinguish redistribution from removal.
- Less injury after separating renewal in time could be credited to OAT1 competition even if the benefit comes from fewer calcium-phosphate particles, less ammonia production or less self-propagating oxidation of fats in cell membranes, the three rival routes. What closes it: Injury reduction must be accompanied by the predicted change in the toxic substance’s persistence and its measured dependence on competition. The supplied proposal identifies a discriminating alternative: preventing mineral-particle formation while leaving anion secretion, the transport of negatively charged substances into urine, unchanged. Protection in that condition without the predicted retention would favor the particle explanation.
What would make this wrong. The central prediction would fail if, for verified OAT1-transported substances with independently measured free concentrations, binding strengths and functional transport, replacing a companion substance with a stronger competitor did not prolong the toxic substance’s persistence as predicted, or separating their arrival did not remove that delay. Protection from blocking mineral-particle formation despite unchanged anion secretion and no predicted retention would instead favor the supplied particle rival. Even a confirmed transport delay would leave the final link unsupported if reducing it did not reduce lasting injury.
What it would change. If the mechanism held, attempts to extend life by imitating tissue renewal would need to account for which waste products arrive together and how strongly they compete, rather than judging removal from daily totals alone. Preserving the useful renewal response could require distributing it across time. Success in cells, an isolated kidney supplied with circulating fluid, or mice would still not establish longer human life or lasting protection of kidneys and blood vessels. The proposal also predicts stabilization of SPV_6, but the supplied material does not define that measure, so this part of the claim cannot be interpreted.
Sources read · 10
Interactions Between Meropenem and Renal Drug Transporters. · Current drug metabolism · 2022
“Among five tested antibiotics, moderate inhibition on OAT3-mediated meropenem uptake was observed for linezolid (IC 50 value was 69.2 μM), weak inhibition was observed for piperacillin, benzylpenicillin, and tazobactam (IC 50 values were 282.2, 308.0 and 668.1 μM, respectively), and no inhibition was observed for sulbactam.”
Does not settle: Источник показывает различную степень подавления переноса меропенема через OAT3 антибиотиками в клеточной модели, но не устанавливает конкуренцию токсичных метаболитов за OAT1, вытеснение по сродству, влияние синхронного обновления тканей, межцикловую задержку анионов, достаточность суточного выведения, стабилизацию SPV_6 или уменьшение хронического повреждения почек и сосудов.
Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2. · Acta pharmacologica Sinica · 2020
“However, the inhibitory effects of LEF/TER on OAT1/3 reduced the tubular cells’ uptake of acyclovir and increased the plasma concentration.”
Does not settle: Источник показывает влияние ингибирования OAT1/3 на перенос ацикловира, но не исследует конкуренцию химически разных продуктов с различным сродством к OAT1, синхронное или разнесённое обновление тканей, межцикловую задержку токсичных анионов, суммарное суточное выведение, SPV_6 либо хроническое повреждение почек и сосудов.
In vitro evaluation of potential transporter-mediated drug interactions of evogliptin. · Biopharmaceutics & drug disposition · 2017
“In similar cellular uptake and bidirectional studies with probe substrates of P-gp, BCRP, OAT1, OAT3, OCT2, OATP1B1 and OATP1B3, the active transport of the substrates was not significantly suppressed by evogliptin.”
Does not settle: Источник рассматривает только влияние эвоглиптина на переносчики в клеточных моделях. Он не исследует конкуренцию химически разных продуктов обмена за OAT1, синхронное или разнесённое обновление тканей, межцикловую задержку токсичных анионов, суммарное суточное выведение, SPV_6 либо хроническое повреждение почек и сосудов.
Effect of Korean Red Ginseng extracts on drug-drug interactions. · Journal of ginseng research · 2018
“The OAT family mediates the uptake of structurally diverse substrates: endogenous compounds (steroids, cyclic nucleotides, and neurotransmitters), drugs (nonsteroidal antiinflammatory drugs, diuretics, and antibiotics), environmental toxins, and other organic waste .”
Does not settle: Источник не исследует конкуренцию субстратов за OAT1, различия в сродстве, синхронное или разнесённое обновление тканей, межцикловую задержку токсичных анионов, SPV_6, суточное выведение либо хроническое повреждение почек и сосудов.
Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats. · Journal of pharmaceutical sciences · 2014
“The cumulative urinary excretion and renal clearance of the two drugs in rats decreased after intravenous coadministration.”
Does not settle: The abstract does not establish competition between tissue-renewal metabolites, an affinity-based displacement hierarchy, retention of a more toxic anion despite adequate daily excretion, effects of staggered versus synchronized renewal, stabilization of SPV_6, or chronic kidney and vascular outcomes. It reports coadministration effects for bestatin and valsartan in rats and transporter assays involving OAT1/3.
Bezafibrate-mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats. · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2016
“It indicated that mizoribine could inhibit the uptake of bezafibrate by hOAT1/3-HEK293 cells in a competitive way.”
Does not settle: Источник показывает конкурентное взаимодействие двух лекарств через OAT1 и OAT3 в клеточной системе и изменение фармакокинетики безафибрата у крыс. Он не устанавливает последствия синхронного обновления тканей, конкуренцию эндогенных токсичных метаболитов, межцикловую задержку, достаточность суммарного суточного выведения, стабилизацию SPV_6 или снижение хронического повреждения почек и сосудов.
OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. · International journal of pharmaceutics · 2018
“This indicated that piperacillin inhibited the uptake of tazobactam in a competitive manner.”
Does not settle: Источник показывает конкурентное взаимодействие двух лекарственных веществ через OAT1/3, но не устанавливает последствия синхронного обновления тканей, задержку токсичных метаболитов, достаточность суммарного суточного выведения, динамику SPV_6 или хроническое повреждение почек и сосудов.
Organic anion transporters also mediate the drug-drug interaction between imipenem and cilastatin. · Asian journal of pharmaceutical sciences · 2020
“Moreover, the K m values of cilastatin were increased in the presence of imipenem with unchanged V max , indicating that imipenem inhibited the uptake of cilastatin in a competitive manner.”
Does not settle: Источник показывает конкурентное взаимодействие имипенема и циластатина при переносе через OAT1 и OAT3 в клеточных моделях и у крыс. Он не исследует продукты обновления тканей, различия их токсичности и сродства, синхронные или разнесённые потоки, достаточность суммарного суточного выведения, SPV_6, а также хроническое повреждение почек и сосудов.
Immunocytochemical characterization of the incubated rat renal cortical slices. · Pflugers Archiv : European journal of physiology · 2005
“The immunostaining experiments indicated a fast, time-dependent loss of basolateral transporters, at a rate of OAT1 > Na/K-ATPase > OAT3.”
Does not settle: The source does not establish competition between chemically distinct metabolites for OAT1, affinity-dependent displacement, retention or toxicity of a lower-affinity anion, effects of synchronized versus staggered tissue renewal, adequate daily excretion despite transient retention, stabilization of SPV_6, or chronic kidney and vascular outcomes.
Evaluation of Puberulic Acid-Induced Nephrotoxicity Using 3D-RPTEC. · Biological & pharmaceutical bulletin · 2025
“Furthermore, the uptake of OAT1 substrate furosemide by OAT1- expressing HEK293 cells was reduced by puberulic acid with an IC 50 value of 5.4 μM.”
Does not settle: Источник показывает лишь снижение захвата фуросемида под действием пуберуловой кислоты в клетках HEK293 с экспрессией OAT1. Он не исследует синхронное или разнесённое обновление тканей, конкуренцию нескольких эндогенных продуктов, межцикловую задержку токсичных анионов, суммарное суточное выведение, SPV_6 либо хроническое повреждение почек и сосудов.
The gap this hypothesis explains
Something is claimed here, but it rests on evidence too thin to carry weight.
Can aligning tissue cycles with a mimic shorten life by overloading kidneys, while staggered cycles preserve benefit?
Original wording · exactly as the pipeline generated it
Может ли синхронизация тканевых циклов миметиком сокращать жизнь, создавая пики продуктов распада выше мощности почечного выведения, тогда как устойчивый сдвиг фаз между тканями сохраняет пользу?
What this question is asking
The question concerns whether a substance that imitates a beneficial bodily process could become harmful by making different tissues cycle together. It asks whether this alignment makes tissues release breakdown products simultaneously, creating peaks that exceed the kidneys’ ability to remove them and ultimately shorten life. The comparison is with tissue cycles that maintain stable timing offsets, which the question assumes might preserve the substance’s benefit. It also asks whether these timing relationships recover after changes in daily routines, without waste accumulating across successive cycles or organ function deteriorating. The supplied material identifies neither a particular substance nor particular breakdown products.
- Mimic or imitation substance
- A substance intended to reproduce an effect of a natural bodily process. This names a broad approach, not an identified treatment; the supplied material specifies no substance or established lifespan benefit.
- Tissue cycles and tissue clocks
- Repeating patterns of activity within parts of the body, and the timing systems associated with those patterns. The question does not identify which tissue activities would generate the proposed waste.
- Alignment and stable timing offsets
- Alignment here means making relevant tissue activities occur together. Stable offsets mean those activities remain separated by consistent intervals; this differs from timing relationships becoming unstable after repeated schedule changes.
- Breakdown products
- Substances produced when biological material is broken down. The question treats them as a potential removal burden, but does not identify them or establish that their removal depends on the kidneys.
- Kidney removal capacity
- The amount of a substance the kidneys can remove over a period of time. No substance-specific capacity or overload threshold is supplied.
- Circadian timing and daily physiological patterns
- Circadian timing concerns approximately daily biological rhythms. Physiological patterns are recurring changes in bodily functions; S2 examines changes in such patterns during drug treatment.
- Internal misalignment
- A mismatch among timing processes inside an organism. S4 supports an explanation involving this mismatch, but the supplied quotation does not specify the relevant relationships or equate them with stable tissue offsets.
- Melatonin
- The biological substance whose production S1 discusses in relation to nighttime light exposure. The supplied quotation does not establish a role for it in the proposed kidney-overload mechanism.
- Gemcitabine
- The anticancer drug studied in S2. Its timing-related toxicity findings do not establish effects of a substance intended to imitate a beneficial physiological process.
- Mammals, mice and Syrian hamsters
- Mammals are the animal group discussed in S3; mice and Syrian hamsters are distinct mammals studied in S2 and S4. Findings in these study animals do not by themselves establish the proposed effect in humans or other species.
- Cry1 and cell differentiation
- Cry1 is the regulator named in S4’s quoted conclusion. Cell differentiation means cells developing specialized identities or roles; the quotation links Cry1 to this process without establishing the proposed kidney or lifespan effects.
- Formation of new nerve cells
- The process also called neurogenesis, which S4 studied in adult hamsters. It is a different measured outcome from kidney function or lifespan.
A mimic can align tissue cycles so that breakdown-product peaks exceed kidney removal capacity, whereas stable timing offsets between tissues preserve its benefit.
The assumption concerns tissues with repeating activity patterns, a substance intended to imitate a bodily process, and kidneys that remove the resulting waste. It assumes that making these activities coincide can overwhelm removal, while keeping them predictably separated retains a beneficial effect. That distinction is needed to attribute different lifespan outcomes to the relative timing of tissue activity.
S3 establishes background organization of bodily timing, but does not establish simultaneous waste release or kidney overload. S1 and S2 concern timing disturbances in other settings. S4 supports an internal-misalignment interpretation in female Syrian hamsters exposed to repeated changes in the light cycle, which complicates a general claim that timing differences are protective but does not test stable offsets. This small set of mostly background sources is too thin to establish or refute the premise.S1S2S3S4
The same question asked without the part nothing read establishes:
- Does aligning tissue cycles with a substance that imitates a bodily process change breakdown-product peaks, kidney function or lifespan compared with stable timing offsets?
- After changes in daily routines, how do tissue timing relationships relate to waste accumulation and kidney function during treatment with such a substance?
- Alignment shortens life; stable offsets retain benefit Under the proposed mechanism, simultaneous tissue activity would concentrate waste release beyond kidney removal capacity, and repeated accumulation would impair function. Stable offsets would spread that demand over time, making relative tissue timing a condition of the substance’s benefit.
- Alignment retains benefit without kidney overload If removal keeps pace with release, coincident tissue activity would not produce the proposed recurring accumulation. The proposed kidney mechanism would then provide no basis for expecting stable offsets to improve lifespan relative to alignment.
- Neither timing pattern preserves benefit If stable offsets also fail to preserve function or lifespan, separating tissue activity in time would not provide the protection assumed by the question. The proposed contrast between harmful alignment and beneficial offsets would then fail, even if alignment itself proved harmful.
The proposed chain begins with an imitation substance changing when tissue processes occur. If those processes release substances requiring kidney removal, simultaneous release could concentrate the removal demand into a shorter period. If that demand exceeded removal capacity, the question proposes that repeated accumulation could impair function and reduce lifespan; the supplied sources do not establish these steps. Treating alignment as automatically beneficial could therefore overlook the proposed overload, while treating staggered timing as automatically protective could overlook consequences of disrupted internal timing.
Согласование часов имеет RL-1; транспортный механизм RL-2 описывает ограниченное выведение, но совместное действие с синхронизирующим миметиком не проверено.
После сдвигов распорядка фазовые отношения стабилизируются; остаточная нагрузка между циклами остаётся ограниченной, функция сохраняется в допустимых пределах.
Не установлено, повышает ли синхронизация устойчивость миметического ответа или создаёт повторяющуюся перегрузку почек при обычных колебаниях распорядка.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Синхронный миметик обновления тканей создаёт конкуренцию химически разных продуктов за переносчик органических анионов OAT1. Метаболит с высоким сродством занимает большую долю транспортных циклов, задерживая более токсичный конкурент с меньшим сродством. Поэтому вред зависит от состава совпавших потоков, даже когда суммарное суточное выведение остаётся достаточным. Разнесённое обновление уменьшает конкурентное вытеснение и межцикловую задержку токсичных анионов. Такой миметик воспроизводит распределённую во времени физиологическую очистку, стабилизирует SPV_6 и предположительно уменьшает хроническое повреждение почек и сосудов.
Where the idea comes from
The hypothesis borrows a result from another field. This is what it borrows, and from where.
Экономика распределения ограниченного ресурса и теория аукционов: пропорциональное распределение в конкурсе Таллока, p_i = b_i / Σ_j b_j. Здесь i и j обозначают конкурирующие метаболиты; b_i = C_i,u / K_i, где C_i,u есть измеренная свободная концентрация метаболита у переносчика, а K_i есть экспериментальная константа конкурентного связывания. p_i соответствует доле занятых транспортных центров, приходящейся на метаболит i. С учётом незанятых центров проверяемое расширение имеет вид q_i = b_i / (1 + Σ_j b_j), J_i = E_T k_i q_i. q_i есть доля всех центров, занятая субстратом i; E_T есть молярное количество функционального переносчика; k_i есть частота переноса связанного субстрата; J_i есть поток захвата в моль за единицу времени. Все параметры оцениваются независимо. Переносится правило распределения, без предположений о целеполагании или стратегическом поведении молекул. [Формальная модель конкурса Таллока](https://link.springer.com/article/10.1007/s10058-022-00315-5).
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
При одинаковом молярном поступлении продуктов замена одного сопутствующего метаболита на менее токсичный, но более сильный конкурент OAT1 увеличит время пребывания другого, токсичного субстрата. Разведение этих двух потоков во времени устранит задержку. Эффект должен количественно следовать независимо измеренным концентрациям свободных веществ и их сродству к переносчику. Если задержка отсутствует, а повреждение предотвращается подавлением образования минеральных частиц при неизменной секреции анионов, преимущество получает IH_Q_L3_M_G3_2_03.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies a directional change in substrate residence time, its disappearance upon temporal separation, a quantitative relationship, and an explicit condition favoring an alternative. No rival prediction was supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Конкуренцию можно измерить в клетках с OAT1, затем проверить в перфузируемой почке и у мышей. Нужно отдельно оценивать свободную фракцию субстратов, базолатеральный захват и выход в мочу: усиленный захват канальцем может сопровождаться внутриклеточным накоплением. Проверка относится только к экспериментально установленным субстратам одного переносчика.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
При одинаковом молярном поступлении продуктов замена одного сопутствующего метаболита на менее токсичный, но более сильный конкурент OAT1 увеличит время пребывания другого, токсичного субстрата. Разведение этих двух потоков во времени устранит задержку. Эффект должен количественно следовать независимо измеренным концентрациям свободных веществ и их сродству к переносчику. Если задержка отсутствует, а повреждение предотвращается подавлением образования минеральных частиц при неизменной секреции анионов, преимущество получает Synchronized tissue renewal may harm kidneys by forming calcium-phosphate particles.
- What would separate them
Synchronized tissue renewal may make kidneys amplify ammonia loading in the blood predicts: При одинаковом обновлении тканей за цикл синхронный режим увеличит положительный почечный артериовенозный баланс аммиака. Введение глутамина с меткой 15N покажет почечное происхождение дополнительного потока. Частичное индуцируемое подавление почечной глутаминазы уменьшит системный пик аммиака и восстановит функцию, хотя выведение аммония с мочой снизится. Эффект должен сохраняться при сопоставимых кислотно-основном состоянии и фильтрации. Отсутствие дополнительного почечного образования аммиака при наличии конкурентной задержки органических анионов поддержит this hypothesis.
- What would separate them
Synchronized tissue renewal may harm kidneys by forming calcium-phosphate particles predicts: Синхронный режим увеличит количество минеральных частиц до появления признаков повреждения канальцев. В перфузионной модели удаление частиц с восстановлением исходного состава растворённых веществ уменьшит повреждение; возврат выделенной фракции восстановит его. Краткое торможение образования частиц пирофосфатом должно защищать при сохранённых потоках органических анионов и азота. Если повреждение сохраняется после удаления частиц и исчезает только при подавлении липидного окисления, преимущество получает Synchronized membrane renewal may trigger self-sustaining lipid oxidation in kidney tubules.
- Rival 03 of 03What would separate them
Synchronized membrane renewal may trigger self-sustaining lipid oxidation in kidney tubules predicts: После синхронного цикла окисление мембран канальцев продолжит нарастать уже после снижения поступления продуктов из обновляемых тканей. Липрокстатин-1 либо независимое генетическое уменьшение чувствительности канальцев к ферроптозу предотвратит потерю функции при неизменных почечном образовании аммиака, конкурентной секреции органических анионов и количестве минеральных частиц. Защита должна возникать и при начале вмешательства после окончания входного липидного импульса. Если функция восстанавливается исключительно вслед за снижением конкурентной задержки анионов, преимущество получает this hypothesis.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.